{
  "id": [
    "24909170"
  ],
  "source": [
    "MED"
  ],
  "pmid": [
    "24909170"
  ],
  "pmcid": [
    "PMC4261066"
  ],
  "doi": [
    "10.1038/onc.2014.161"
  ],
  "title": [
    "Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells."
  ],
  "authorString": [
    "Wang J, Mikse O, Liao RG, Li Y, Tan L, Janne PA, Gray NS, Wong KK, Hammerman PS."
  ],
  "authorList": [
    {
      "author": [
        {
          "fullName": [
            "Wang J"
          ],
          "firstName": [
            "J"
          ],
          "lastName": [
            "Wang"
          ],
          "initials": [
            "J"
          ],
          "affiliation": [
            "1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA [2] Department of Integrative Medicine and Neurobiology, Shanghai Medical College, Fudan University, Shanghai, China."
          ]
        },
        {
          "fullName": [
            "Mikse O"
          ],
          "firstName": [
            "O"
          ],
          "lastName": [
            "Mikse"
          ],
          "initials": [
            "O"
          ],
          "affiliation": [
            "Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA."
          ]
        },
        {
          "fullName": [
            "Liao RG"
          ],
          "firstName": [
            "R G"
          ],
          "lastName": [
            "Liao"
          ],
          "initials": [
            "RG"
          ],
          "authorId": [
            {
              "_": "0000-0002-7830-1976",
              "$": {
                "type": "ORCID"
              }
            }
          ],
          "affiliation": [
            "1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA [2] Broad Institute of Harvard and MIT, Cambridge, MA, USA."
          ]
        },
        {
          "fullName": [
            "Li Y"
          ],
          "firstName": [
            "Y"
          ],
          "lastName": [
            "Li"
          ],
          "initials": [
            "Y"
          ],
          "affiliation": [
            "1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA [2] Broad Institute of Harvard and MIT, Cambridge, MA, USA."
          ]
        },
        {
          "fullName": [
            "Tan L"
          ],
          "firstName": [
            "L"
          ],
          "lastName": [
            "Tan"
          ],
          "initials": [
            "L"
          ],
          "affiliation": [
            "Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA."
          ]
        },
        {
          "fullName": [
            "Janne PA"
          ],
          "firstName": [
            "P A"
          ],
          "lastName": [
            "Janne"
          ],
          "initials": [
            "PA"
          ],
          "affiliation": [
            "1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA [2] Belfer Institute of Applied Cancer Sciences, Boston, MA, USA."
          ]
        },
        {
          "fullName": [
            "Gray NS"
          ],
          "firstName": [
            "N S"
          ],
          "lastName": [
            "Gray"
          ],
          "initials": [
            "NS"
          ],
          "affiliation": [
            "Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA."
          ]
        },
        {
          "fullName": [
            "Wong KK"
          ],
          "firstName": [
            "K-k"
          ],
          "lastName": [
            "Wong"
          ],
          "initials": [
            "KK"
          ],
          "affiliation": [
            "1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA [2] Belfer Institute of Applied Cancer Sciences, Boston, MA, USA."
          ]
        },
        {
          "fullName": [
            "Hammerman PS"
          ],
          "firstName": [
            "P S"
          ],
          "lastName": [
            "Hammerman"
          ],
          "initials": [
            "PS"
          ],
          "affiliation": [
            "1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA [2] Broad Institute of Harvard and MIT, Cambridge, MA, USA."
          ]
        }
      ]
    }
  ],
  "authorIdList": [
    {
      "authorId": [
        {
          "_": "0000-0002-7830-1976",
          "$": {
            "type": "ORCID"
          }
        }
      ]
    }
  ],
  "journalInfo": [
    {
      "issue": [
        "17"
      ],
      "volume": [
        "34"
      ],
      "journalIssueId": [
        "2277378"
      ],
      "dateOfPublication": [
        "2015 Apr"
      ],
      "monthOfPublication": [
        "4"
      ],
      "yearOfPublication": [
        "2015"
      ],
      "printPublicationDate": [
        "2015-04-01"
      ],
      "journal": [
        {
          "title": [
            "Oncogene"
          ],
          "ISOAbbreviation": [
            "Oncogene"
          ],
          "medlineAbbreviation": [
            "Oncogene"
          ],
          "NLMid": [
            "8711562"
          ],
          "ISSN": [
            "0950-9232"
          ],
          "ESSN": [
            "1476-5594"
          ]
        }
      ]
    }
  ],
  "pubYear": [
    "2015"
  ],
  "pageInfo": [
    "2167-2177"
  ],
  "abstractText": [
    "Somatic alterations of fibroblast growth factor receptors (FGFRs) have been described in a wide range of malignancies. A number of anti-FGFR therapies are currently under investigation in clinical trials for subjects with FGFR gene amplifications, mutations and translocations. Here, we develop cell line models of acquired resistance to FGFR inhibition by exposure of cell lines harboring FGFR3 gene amplification and translocation to the selective FGFR inhibitor BGJ398 and multitargeted FGFR inhibitor ponatinib. We show that the acquisition of resistance is rapid, reversible and characterized by an epithelial to mesenchymal transition and a switch from dependency on FGFR3 to ERBB family members. Acquired resistance was associated with demonstrable changes in gene expression including increased production of ERBB2/3 ligands, which were sufficient to drive resistance in the setting of FGFR3 dependency but not dependency on other FGFR family members. These data support the concept that activation of ERBB family members is sufficient to bypass dependency on FGFR3 and suggest that concurrent inhibition of these two pathways may be desirable when targeting FGFR3-dependent cancers."
  ],
  "affiliation": [
    "1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA [2] Department of Integrative Medicine and Neurobiology, Shanghai Medical College, Fudan University, Shanghai, China."
  ],
  "language": [
    "eng"
  ],
  "pubModel": [
    "Print-Electronic"
  ],
  "pubTypeList": [
    {
      "pubType": [
        "Journal Article",
        "Research Support, Non-U.S. Gov't",
        "Research Support, U.S. Gov't, Non-P.H.S.",
        "Research Support, N.I.H., Extramural"
      ]
    }
  ],
  "grantsList": [
    {
      "grant": [
        {
          "grantId": [
            "K08 CA163677"
          ],
          "agency": [
            "NCI NIH HHS"
          ],
          "acronym": [
            "CA"
          ],
          "orderIn": [
            "0"
          ]
        },
        {
          "grantId": [
            "R01 CA140594"
          ],
          "agency": [
            "NCI NIH HHS"
          ],
          "acronym": [
            "CA"
          ],
          "orderIn": [
            "0"
          ]
        },
        {
          "grantId": [
            "P01 CA154303"
          ],
          "agency": [
            "NCI NIH HHS"
          ],
          "acronym": [
            "CA"
          ],
          "orderIn": [
            "0"
          ]
        }
      ]
    }
  ],
  "meshHeadingList": [
    {
      "meshHeading": [
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Cell Line, Tumor"
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Humans"
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Phenylurea Compounds"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "PD"
                  ],
                  "qualifierName": [
                    "pharmacology"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Imidazoles"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "PD"
                  ],
                  "qualifierName": [
                    "pharmacology"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Pyridazines"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "PD"
                  ],
                  "qualifierName": [
                    "pharmacology"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Pyrimidines"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "PD"
                  ],
                  "qualifierName": [
                    "pharmacology"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Receptor, erbB-2"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "GE"
                  ],
                  "qualifierName": [
                    "genetics"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                },
                {
                  "abbreviation": [
                    "ME"
                  ],
                  "qualifierName": [
                    "metabolism"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Receptor, erbB-3"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "GE"
                  ],
                  "qualifierName": [
                    "genetics"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                },
                {
                  "abbreviation": [
                    "ME"
                  ],
                  "qualifierName": [
                    "metabolism"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Protein Kinase Inhibitors"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "PD"
                  ],
                  "qualifierName": [
                    "pharmacology"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Enzyme Activation"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "DE"
                  ],
                  "qualifierName": [
                    "drug effects"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                },
                {
                  "abbreviation": [
                    "GE"
                  ],
                  "qualifierName": [
                    "genetics"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Drug Resistance, Neoplasm"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "DE"
                  ],
                  "qualifierName": [
                    "drug effects"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                },
                {
                  "abbreviation": [
                    "GE"
                  ],
                  "qualifierName": [
                    "genetics"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Receptor, Fibroblast Growth Factor, Type 3"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "AI"
                  ],
                  "qualifierName": [
                    "antagonists & inhibitors"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                },
                {
                  "abbreviation": [
                    "GE"
                  ],
                  "qualifierName": [
                    "genetics"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                },
                {
                  "abbreviation": [
                    "ME"
                  ],
                  "qualifierName": [
                    "metabolism"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "Y"
          ],
          "descriptorName": [
            "Epithelial-Mesenchymal Transition"
          ]
        }
      ]
    }
  ],
  "chemicalList": [
    {
      "chemical": [
        {
          "name": [
            "Pyrimidines"
          ],
          "registryNumber": [
            "0"
          ]
        },
        {
          "name": [
            "Imidazoles"
          ],
          "registryNumber": [
            "0"
          ]
        },
        {
          "name": [
            "Pyridazines"
          ],
          "registryNumber": [
            "0"
          ]
        },
        {
          "name": [
            "Protein Kinase Inhibitors"
          ],
          "registryNumber": [
            "0"
          ]
        },
        {
          "name": [
            "Phenylurea Compounds"
          ],
          "registryNumber": [
            "0"
          ]
        },
        {
          "name": [
            "ERBB2 protein, human"
          ],
          "registryNumber": [
            "EC 2.7.10.1"
          ]
        },
        {
          "name": [
            "Receptor, Fibroblast Growth Factor, Type 3"
          ],
          "registryNumber": [
            "EC 2.7.10.1"
          ]
        },
        {
          "name": [
            "Receptor, erbB-2"
          ],
          "registryNumber": [
            "EC 2.7.10.1"
          ]
        },
        {
          "name": [
            "Receptor, erbB-3"
          ],
          "registryNumber": [
            "EC 2.7.10.1"
          ]
        },
        {
          "name": [
            "3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea"
          ],
          "registryNumber": [
            "0"
          ]
        },
        {
          "name": [
            "FGFR3 protein, human"
          ],
          "registryNumber": [
            "EC 2.7.10.1"
          ]
        },
        {
          "name": [
            "ponatinib"
          ],
          "registryNumber": [
            "4340891KFS"
          ]
        },
        {
          "name": [
            "ERBB3 protein, human"
          ],
          "registryNumber": [
            "EC 2.7.10.1"
          ]
        }
      ]
    }
  ],
  "subsetList": [
    {
      "subset": [
        {
          "code": [
            "IM"
          ],
          "name": [
            "Index Medicus"
          ]
        }
      ]
    }
  ],
  "fullTextUrlList": [
    {
      "fullTextUrl": [
        {
          "availability": [
            "Open access"
          ],
          "availabilityCode": [
            "OA"
          ],
          "documentStyle": [
            "pdf"
          ],
          "site": [
            "Europe_PMC"
          ],
          "url": [
            "http://europepmc.org/articles/PMC4261066?pdf=render"
          ]
        },
        {
          "availability": [
            "Open access"
          ],
          "availabilityCode": [
            "OA"
          ],
          "documentStyle": [
            "html"
          ],
          "site": [
            "Europe_PMC"
          ],
          "url": [
            "http://europepmc.org/articles/PMC4261066"
          ]
        },
        {
          "availability": [
            "Subscription required"
          ],
          "availabilityCode": [
            "S"
          ],
          "documentStyle": [
            "doi"
          ],
          "site": [
            "DOI"
          ],
          "url": [
            "http://dx.doi.org/10.1038/onc.2014.161"
          ]
        }
      ]
    }
  ],
  "isOpenAccess": [
    "Y"
  ],
  "inEPMC": [
    "Y"
  ],
  "inPMC": [
    "N"
  ],
  "hasPDF": [
    "Y"
  ],
  "hasBook": [
    "N"
  ],
  "hasSuppl": [
    "N"
  ],
  "citedByCount": [
    "2"
  ],
  "hasReferences": [
    "Y"
  ],
  "hasTextMinedTerms": [
    "Y"
  ],
  "hasDbCrossReferences": [
    "Y"
  ],
  "dbCrossReferenceList": [
    {
      "dbName": [
        "UNIPROT"
      ]
    }
  ],
  "hasLabsLinks": [
    "Y"
  ],
  "epmcAuthMan": [
    "N"
  ],
  "hasTMAccessionNumbers": [
    "N"
  ],
  "dateOfCompletion": [
    "2015-06-29"
  ],
  "dateOfCreation": [
    "2015-04-24"
  ],
  "dateOfRevision": [
    "2016-11-25"
  ],
  "electronicPublicationDate": [
    "2014-06-09"
  ],
  "firstPublicationDate": [
    "2014-06-09"
  ],
  "embargoDate": [
    "2015-10-23"
  ]
}